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2014, accepted Jantherosclerosis research has classically followed 2 intertwining lines of investigation concerning atherosclerosis as a
local process (the “high-risk plaque”) and as a systemic disease (the “high-risk patient”). Over time, the weight of
attention has swung, like a pendulum, between these 2 related foci. With optimal medical therapy and attention to
risk factors ﬁrmly established as fundamental aspects of management, in the past year, we have nevertheless
perceived a shift in the pendulum toward renewed focus on the local plaque. We contend that this shift results from
a convergence of major advances in understanding the biology of plaque progression, novel sophisticated invasive
and noninvasive imaging modalities for the in vivo characterization of plaque composition and inﬂammation, and
emerging data and technologies that have renewed interest in locally targeted interventions. Here, we review the
dynamic and exciting progress that has occurred over the last 12 months in this arena, while acknowledging future
work that remains to be done to reﬁne and validate new imaging modalities and therapies. (J Am Coll Cardiol
2014;63:1604–16) ª 2014 by the American College of Cardiology FoundationAtherosclerotic plaque is the local manifestation of a sys-
temic disease. As such, research in this ﬁeld has generally
followed 2 intertwining lines of investigation, focused either
on the local process (the “high-risk plaque”) or the systemic
disease (the “high-risk patient”) (1). Over time, the weight
of collective attention has swung like a pendulum between
these related foci. Two decades ago, observations on the
natural history of coronary plaque (2) and newly available
intravascular tools such as intravascular ultrasound (IVUS),
virtual histology, palpography, and thermography fueled
interest in the local plaque. Emphasis on understanding,
diagnosing, and treating atherosclerosis as a systemic disease
then took hold as medications, rather than locally targeted
therapies, demonstrated efﬁcacy in reducing myocardial
infarction (MI) and death. In the last decade, this shift was
punctuated by results of the COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive druG
Evaluation) trial in which an initial strategy of local therapy
(revascularization) conferred no advantage for prevention of
the composite of death or nonfatal MI above and beyond
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uary 28, 2014.On this backdrop of optimal medical therapy and risk
factor modiﬁcation, now established as the bedrock of
atherosclerosis management, efforts over the past year to
understand, diagnose, and treat the local atherosclerotic
plaque have gained momentum (Fig. 1). Central to this
resurgence of interest in the high-risk plaque is the arrival of
diverse new tools for invasive and noninvasive plaque im-
aging. Informed by advances in our understanding of both
the pathology of the local plaque and the molecular mech-
anisms of systemic atherosclerosis, these novel imaging
approaches provide opportunities to describe, not only the
anatomy, but also the biology of the plaque in vivo. In this
narrative review, we aim to synthesize key ﬁndings over the
past year in atherosclerosis, plaque biology, plaque imaging,
and emerging therapies.Deﬁning the High-Risk Plaque
Pathological observations. Core insights informing our
paradigm of the plaque at high risk of rupture have tradi-
tionally derived from pathological observations of ruptured
and nonruptured plaques post-mortem (4). Adding to this
body of published data, a recent analysis of 295 plaques in
213 sudden cardiac death victims identiﬁed aspects of plaque
composition and burden as markers of risk. In this study,
Narula et al. (5) compared 105 stable plaques, 88 thin-cap
ﬁbroatheromas (TCFA), and 102 ruptured plaques with
respect to features of plaque morphology: ﬁbrous cap
thickness, percent luminal stenosis, plaque area, necrotic
core area, macrophage area, and calciﬁcation. Fibrous cap
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1605thickness was the best discriminator of plaque type,
measuring <54 mm in ruptured plaques, 54 to 84 mm in
most TCFA, and >84 mm in stable plaques. Upon
exclusion of cap thickness, the best discriminators of
TCFA were macrophage inﬁltration and necrotic core.
In seeming contradistinction to the earlier observation by
Ambrose et al. (2) that incident MI tended to emerge from
previously nonobstructive plaque, the majority of TCFA
in this pathological study exhibited >50% stenosis, and
70% of ruptured plaques showed >75% stenosis. This patho-
logical observation is consistent with angiographic ﬁndings
in a substudy of the COURAGE trial in which non-
revascularized, 50% lesions predicted subsequent acute cor-
onary syndromes (ACS) (6) and IVUS ﬁndings in the
PROSPECT (ProspectiveNatural-History Study of Coronary
Atherosclerosis) in which nonculprit lesions responsible for
subsequent ischemic events were associated with large plaque
burden and reduced minimal luminal area despite apparently
mild luminal narrowing at angiography (7).
Reconciling these observations may be important to
deﬁning the high-risk plaque, as reviewed recently by Puri
et al. (8). It is possible that seemingly nonobstructive plaque
at initial angiography represents the “tip of the iceberg,” with
signiﬁcant plaque burden not detected by angiography
because of positive (outward) remodeling. Alternatively, MI
may be associated with rapid plaque progression in the
preceding weeks to months, with acceleration of plaque
progression mediated by subclinical cycles of plaque rupture
and healing (9) or intraplaque hemorrhage (as seen in carotid
plaque) (10).
Molecular and cellular basis of plaque progression.
Advances in understanding of the cellular and molecular
basis for plaque progression have helped to deﬁne markers
of plaque vulnerability with potential application to both
imaging and therapy.
A ﬁrst theme has been reﬁnement of our understanding of
the role of macrophages, monocytes and inﬂammation in
plaque progression. Macrophages and monocytes have been
understood classically to contribute to plaque progression
through phagocytosis of cholesterol droplets and debris,
yielding a sequence of foam cell generation, foam cell death,
and formation of the necrotic core, as well as contributing
to inﬂammation and plaque rupture (11). In mouse models,
monocytosis develops after MI or stroke in a sympathetic
nervous system–dependent manner, a potential mechanism
for accelerated atherosclerosis (12). Whether plaque accu-
mulation of macrophages and monocytes results from inﬁl-
tration has now become the subject of controversy following
recent surprising results suggesting that local proliferation
(rather than inﬁltration) accounts for the majority of these
cells within plaques (13,14). There is also suggestion that
neutrophils may precede monocytes at sites of vascular
inﬂammation, on the basis of the ﬁnding in a mouse model
that neutrophil-derived cathelicidins induce adhesion of
circulating monocytes (15). Circulating leukocyte mem-
brane microparticles that become elevated in humans withunstable carotid plaque may be
footprints of this process (16).
Furthermore, there is growing
evidence that molecular inﬂam-
matory mediators associated with
leukocyte activation may relate to
risk of atherosclerosis disease pro-
gression. A key example is inter-
leukin (IL)-6, an inﬂammatory
cytokine associated with increased
C-reactive protein production that
is released by activated leukocytes
and vascular smooth muscle cells
at sites of vascular injury. The po-
tential role of IL-6 signaling in
atherosclerosis progression was
bolstered by recent observations
of signiﬁcant variation in coronary
artery disease (CAD) risk with
the Asp358Ala allelic variant of
the IL-6 receptor (17,18).
A second key theme of publi-cations has been the role of free hemoglobin and oxidative
stress in plaque progression. When free hemoglobin is
released into plaque as a consequence of intraplaque hem-
orrhage, heme iron is a potent generator of reactive oxygen
species (ROS). Binding of free hemoglobin by circulating
haptoglobin attenuates oxidative activity and promotes
clearance of hemoglobin by macrophages via the CD163
scavenger receptor. Unchecked, oxidative activity related to
free hemoglobin may contribute to plaque progression. In a
study of human aortic plaques, a genetic polymorphism at
the haptoglobin locus (Hp2-2) linked to defective attenua-
tion of heme iron–mediated oxidation was associated with a
signiﬁcant increase in apoptotic macrophages, oxidized
phospholipid, and malondialdehyde-like oxidation-speciﬁc
epitopes (19). In addition, among patients with diabetes
mellitus in the Nurses’ Health Study, the Hp2-2 genotype
was associated with a signiﬁcantly increased risk of coronary
heart disease (relative risk 7.90, 95% conﬁdence interval
[CI]: 4.43 to 14.10, p ¼ 0.004) (20).
Free hemoglobin within plaque may inﬂuence differen-
tiation of macrophages into different subtypes and their
capacity to engage in reverse cholesterol transport. Evalu-
ating pathological specimens of human atherosclerotic
plaque, Finn et al. (21) demonstrated that macrophages
with high expression of mannose and CD163 receptors,
devoid of neutral lipids typical of foam cells, preferentially
exist at sites of intraplaque hemorrhage and that intracel-
lular hemoglobin in a rabbit model is necessary to drive
differentiation of this macrophage subtype, M(Hb).
Whereas M(Hb) was associated with increased ferroportin
expression, reduced intracellular iron, reduced ROS,
increased liver X receptor alpha (LXRa) activation and
cholesterol efﬂux via ATP binding cassette (ABC) trans-
porters, degradation of ferroportin using hepcidin increased
Figure 1 Swinging Focus of Interest in Atherosclerosis
Concept of a swinging focus of interest in atherosclerosis and high-risk plaques, and potential factors driving this changing interest.
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and cholesterol efﬂux.
Emerging evidence suggests that, in addition to and inde-
pendent of ROS, damage to mitochondrial DNA (mtDNA)
may promote atherosclerotic plaque progression (22). In
apolipoprotein E-null mice, mtDNA damage was observed
early in the vessel wall preceding signiﬁcant atherosclerosis.
Mice bred for deﬁciency in mitochondrial polymerase-g
proofreading activity, yielding extensive mtDNA damage,
demonstrated impaired oxidative phosphorylation without
increase in ROS, along with hyperlipidemia, vascular smooth
muscle cell apoptosis, and atherosclerosis. In humans,
mtDNA damage in leukocytes was associated with plaque
high-risk features on radiofrequency (“virtual histology”)
intravascular ultrasound (RF-IVUS).
A third key theme was the role of lipid mediators, in
particular, high-density lipoprotein (HDL), in plaque
biology. Classical hypotheses as to the role of HDL in
plaque progression have centered on cholesterol efﬂux from
foam cells or reverse cholesterol transport, yielding reduction
in lesion size or inﬂammation (23). Despite a consistent
observation of an inverse relationship between high-density
lipoprotein cholesterol (HDL-C) and CAD risk in epide-
miological studies; however, the mechanistic role of HDL-C
in plaque progression has become increasingly controversial
(24), fueled by successive negative trials of HDL-C–raising
therapies, most recently dalcetrapib (25–27). Controversy
was further stoked this year by results of a Mendelian
randomization study showing no association between an
allelic variant of the endothelial lipase gene (LIPG
Asn396Ser) and risk of MI despite a signiﬁcant associated
increase in HDL-C (28). As a possible explanation for these
ﬁndings, it is plausible that the level of HDL-C is merelythe wrong metric of HDL functionality. Recent evidence
has highlighted the importance rather of HDL particle
number (29,30) and the HDL proteome in predicting risk
and plaque progression (31), as well as additional candidate
mediators such as HDL-associated lipoprotein-associated
phospholipase A2 (32). New data on apolipoprotein A1
further underscore the importance of taking caution in
interpretation of investigations on the basis of lipoprotein
particles isolated from plasma or serum, because the distri-
bution and function of these circulating particles may differ
substantially from those found in atherosclerotic plaque (33).
Use of collagen-speciﬁc peptide conjugated HDL nano-
particles as cardiac magnetic resonance imaging (CMR)
contrast agents is under active investigation for the study of
plaque regression (34) and may provide new insights into
HDL distribution and function in vivo.
Although diverse, these molecular advances in our un-
derstanding of plaque biology represent a major step forward
(Fig. 2), and we predict that several of these insights may
shape translational and pre-clinical efforts to therapeutically
modulate plaque biology in the coming years. Selected
additional important new papers are summarized in Table 1
(35–45).
Identifying the High-Risk Plaque In Vivo
By translating features of high-risk plaque and plaque pro-
gression from pathological, molecular, and cellular investi-
gations into imaging, there is the potential to characterize
the risk proﬁle of plaque in vivo. Putative beneﬁts of iden-
tifying high-risk plaque include prediction of atherosclerotic
events, monitoring response to therapy, and targeting ther-
apies to patients and even to speciﬁc lesions. To the extent
Figure 2 Recent Advances in Atherosclerosis
Selected advances in 2012 to 2013 in understanding of local atherosclerotic plaque progression. CAD ¼ coronary artery disease; DNA ¼ deoxyribonucleic acid; HDL ¼ high-
density lipoprotein; IL ¼ interleukin; Lp-PLA2 ¼ lipoprotein-associated phospholipase A2; miRNA ¼ microinhibitory RNA. The ﬁgure was created using Servier medical art
(Servier, Suresnes, France).
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1607that we have witnessed a rebirth of interest in plaque im-
aging, with a proliferation of papers over the past year
(Table 2) (46–52), this ﬁeld remains in its infancy, with
signiﬁcant progress needed to overcome shortcomings of
older technologies and to reﬁne new tools. Here, we high-
light key contributions in the past year.
Grayscale and RF-IVUS. Expanding on the ﬁndings of
the PROSPECT study, additional analyses of RF-IVUS
data from that study have offered insight into differences
in plaque morphology in patient subsets. Patients with
chronic kidney disease, who were more likely to be older,
female, and diabetic, had more extensive, severe athero-
sclerosis than patients without chronic kidney disease,
exhibiting a greater necrotic core burden and less ﬁbrous
tissue (53). Women, despite being older and with greater
prevalence of comorbidities, exhibited less extensive
atherosclerosis than men with fewer nonculprit lesions, less
necrotic core and calcium, and less plaque rupture (6.6% vs.
16.3%, p ¼ 0.002) (54). In women, predictors of major
adverse cardiac events (MACE) at 3 years related to a
nonculprit lesion included plaque burden 70% and TCFA.
Patients with diabetes and metabolic syndrome tended to
exhibit lesions that were longer with greater plaque burden,
smaller luminal area, and greater necrotic core and calciﬁ-
cation, of which necrotic core and calciﬁcation were signif-
icantly associated with future nonculprit MACE (55).
A separate analysis of RF-IVUS in a subset of 63 patients
in the HORIZONS-AMI (Harmonizing Outcomes with
Revascularization and Stents in Acute Myocardial Infarc-
tion) study provided parallel insights in patients afterST-segment elevation MI (56). Of 99 untreated nonculprit
lesions, 41 were TCFA at baseline; at 13-month follow-up,
32 of 41 lesions (78%) remained classiﬁed as TCFA, and an
additional 21 lesions were newly classiﬁed as TCFA,
reclassiﬁed from pathological intimal thickening or thick-
cap ﬁbroatheroma. Lesions categorized as TCFA at base-
line exhibited a decrease in minimal lumen area and an
increase in percent necrotic core at 13-month follow-up.
IVUS has been used to study the relationship between
different patterns of calciﬁcation and plaque progression.
Whereas extensively calciﬁed plaques have been considered
to be less vulnerable to rupture, so-called “spotty” calciﬁ-
cation has been associated with ischemic events. In a serial
IVUS study, Kataoka et al. (57) found that spotty calciﬁ-
cation, deﬁned by lesions 1 to 4 mm in length with an arc
of calcium <90, was associated with male sex, diabetes
mellitus, prior MI, lower on-treatment HDL-C level,
greater percent and total atheroma volume, and greater
progression of percent atheroma volume on subsequent
IVUS examination, despite medical therapy. Conversely,
calciﬁed nodules, deﬁned by IVUS as distinct calciﬁcations
with an irregular, protruding, and convex luminal surface,
may confer a lower risk of ischemic events. In a substudy of
the PROSPECT study, calciﬁed nodules were associated
with older patient age, greater plaque burden, more thick-
cap ﬁbroatheromas, and a lower rate of nonculprit
MACE (58).
Although RF-IVUS–determined TCFA were indepen-
dent predictors of subsequent ischemic events in the
PROSPECT and VIVA (Virtual Histology-IVUS in
Table 1 Selected Additional Studies Exploring the Molecular Basis of Plaque Progression
First Author (Ref. #) Design Methods Findings Implications
Bonaca et al. (35) Randomized
clinical trial,
substudy
Measured PAPP-A, a zinc-binding
metalloproteinase associated with high-
risk plaque, in 3,782 patients with NSTE-
ACS randomized to ranolazine or
placebo.
PAPP-A >6.0 mIU/ml at presentation was
associated with doubling in risk of MI or
CV death at 30 days.
Supports investigation into
PAPP-A as a prognostic
marker, mediator of plaque
progression, and possible
therapeutic target.
Chan et al. (36) Meta-analysis Analyzed 33,673 subjects in 21 studies
with data on angiographic CAD, MI, and
9p21 genotype.
Increased risk of angiographic CAD and
multivessel CAD with 9p21 risk allele,
but not MI.
Implicates 9p21 locus in
atherosclerotic phenotype.
Ganda et al. (37) Cross-sectional Measured cystatin C, blood counts, lipids,
cIMT, and amino acid metabolites
associated with low HDL-C and insulin
resistance.
Monocyte count was associated with cIMT.
High cystatin C, low HDL-C and
metabolites associated with metabolic
syndrome predicted higher monocyte
counts.
Implicates increasing monocyte
levels in atherogenesis in mild
renal dysfunction.
Gupta et al. (38) Cross-sectional Measured CRP, CAC, AWT, and APB in a
multiethnic, population-based
probability sample of adults age 30 to
65 yrs in Dallas County and compared
associations across BMI strata.
C-statistics of CRP for CAC, AWT, and APB
were higher for normal weight than
obese patients.
CRP may be less useful for
prediction of atherosclerotic
burden in obese patients.
Khan et al. (39) Animal model Studied atherosclerosis in LDL-receptor,
GGTase-I knockout mouse model.
GGTase-I deﬁciency was associated with
increased plaque inﬂammation but
decreased plaque area and increased
reverse cholesterol transport.
Contributes to understanding of
mechanisms involving
geranylgeranylation in
atherogenesis and the effects
of statins.
Le et al. (40) Animal model Studied atherosclerosis in an endothelial
cell speciﬁc ERK5 knockout (ERK5-EKO)
mouse.
ERK5-EKO mice showed increased
leukocyte rolling and vascular reactivity,
and increased atherogenesis with LDL-
receptor knockout. P90RSK, increased
in diabetic mouse vessels, inhibited
ERK5 transcriptional activity, reduced
endothelial nitric oxide synthase






Mahabadi et al. (41) Prospective
cohort
Measured EAT by CT and incident coronary
events over 8 yrs follow-up in 4,093
subjects from general population.
Increased risk of fatal and nonfatal
coronary events with doubling of EAT,
independent of clinical risk factors and
CAC.
Identiﬁes EAT as a novel
predictor of coronary events
and raises interest in EAT as a
markerdor mediatordof
coronary atherogenesis.
Mani et al. (42) Animal model CSE knockout mouse. CSE knockout mice experienced early
atherogenesis, which was inhibited by
exogenous hydrogen sulﬁde.
Implicates CSE/H2S pathway in
atherogenesis.




Measured levels of TMAO in human
subjects after a phosphatidylcholine
challenge, before and after broad-
spectrum antibiotics. Measured TMAO in
4,007 patients undergoing elective
coronary angiography.
Antibiotics suppressed TMAO levels.
Plasma TMAO predicted death/MI/
stroke at 3-year follow-up.
Implicates intestinal microbiota
in TMAO generation and
atherosclerosis disease
progression. See also Koeth
et al. (44).
Xiao et al. (45) Animal model Evaluated relationship between disturbed
blood ﬂow patterns, inﬂammasome
induction and atherogenesis in mouse
aorta.
Oscillatory ﬂow induced SREBP2 and
NLRP3 inﬂammasome in endothelial
cells. SREBP2 and NLRP3 were elevated
in atheroprone areas of aorta and
overexpression of SREBP2 increased




APB¼ aortic plaque burden; AWT¼ aortic wall thickness; BMI¼ bodymass index; CAC¼ coronary artery calcium score; CAD¼ coronary artery disease; cIMT¼ carotid intimamedia thickness; CRP¼ C-reactive
protein; CSE¼ cystathionine g-lyase; CT¼ computed tomography; CV¼ cardiovascular; EAT¼ epicardial adipose tissue; ERK5¼ extracellular-signal-regulated kinase 5; GGTase-I¼ geranylgeranyltransferase-I;
HDL-C ¼ high-density lipoprotein cholesterol; LDL ¼ low-density lipoprotein; NLRP3 ¼ NOD-like receptor family, pyrin domain containing 3; NSTE-ACS ¼ non–ST-segment elevation acute coronary syndromes;
MI ¼ myocardial infarction; PAPP-A ¼ pregnancy-associated plasma protein-A; SREBP2 ¼ sterol regulatory element binding protein 2; TMAO ¼ trimethylamine-N-oxide.
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IVUS must be acknowledged (60). Because the axial reso-
lution of RF-IVUS is insufﬁcient to accurately measure
ﬁbrous cap thickness, RF-IVUS deﬁnes TCFA on the basis
of the presence of a necrotic core abutting the lumen,
without evident overlying ﬁbrous tissue, and plaque volume
of 40% on at least 3 consecutive images (61). The accuracy
of necrotic core determination itself has been challenged,albeit in a miniswine model (62). Proper acquisition and
analysis of RF-IVUS is also technically challenging. In
particular, this poses challenges for serial imaging of speciﬁc
lesions.
Optical coherence tomography. Optical coherence to-
mography (OCT), which measures depth-resolved back-
reﬂection of infrared light, provides axial (5 to 20 mm) and
transverse resolution (30 mm) that is far superior to IVUS
Table 2 Selected Additional Studies Exploring Plaque Imaging, Disease Progression, and Risk Prediction
First Author (Ref. #) Design Methods Findings Implications
Baldassarre et al. (46) Prospective cohort Performed carotid ultrasonography in
3,703 subjects with at least 3 risk
factors, with a median 36.2-month
follow-up, and compared the
predictive value of different
approaches to cIMT measurement.
Average of 8 maximal cIMT
measurements, alone or in
combination with interadventitia
common carotid diameter, was
superior for prediction of incident
cardiovascular events compared
with common carotid mean IMT.
All methods provided incremental
improvement over Framingham
scoring.
Reafﬁrmed utility of cIMT in
reclassifying patients at
intermediate (if not high) risk and
raised the question of how to
proceed when cIMT measurement
results in downward
reclassiﬁcation of patients judged
high risk on the basis of clinical
risk factors.
Budoff et al. (47) Prospective cohort Measured CAC at baseline and at a
median 2.5 yrs in 5,682 patients
in the Multi-Ethnic Study of
Atherosclerosis, with a median
clinical follow-up of 7.6 yrs.
CAC progression independently
predicted coronary events after
adjustment for age, sex, ethnicity,
baseline CAC, and other risk
factors.
Provided evidence for CAC
progression as a marker of disease
progression and risk.
Naya et al. (48) Retrospective cohort Evaluated CAC and CFR with respect
to clinical outcomes in 901
consecutive patients undergoing
myocardial perfusion PET (with
normal perfusion) and CT, with a
median 1.53 yrs follow-up.
CFR was inversely related to CAC.
CFR, but not CAC, improved
prediction of MACE.
Provided evidence for CFR as a risk
marker in patients with normal
perfusion.
Rifkin et al. (49) Prospective cohort Examined renal artery calciﬁcation on
screening whole-body computed
tomography in 4,950 community-
dwelling healthy subjects in
relation to all-cause mortality, with
a median 8.2 yrs follow-up.
Renal artery calciﬁcation signiﬁcantly
added to a model incorporating
Framingham risk factors and CAC
in predicting mortality.
Identiﬁed renal artery calciﬁcation as
a novel predictor of all-cause
death.
Sillesen et al. (50) Cross-sectional Measured carotid plaque burden by
3D ultrasound and compared with
CAC, cIMT, abdominal aortic
diameter, and ABI in 6,101
asymptomatic patients.
Carotid plaque burden correlated
with CAC more strongly than did
cIMT, AAD, or ABI.
Identiﬁed carotid plaque burden as a
superior noninvasive predictor of
coronary calciﬁcation, raising
interest in its utility in risk
prediction.
Stone et al. (51) Prospective cohort Performed invasive vascular proﬁling
atbaseline and, in74%of cases,6 to
10months later in 506 patientswith
ACS, with 1-yr clinical follow-up.
Large plaque burden and low local
endothelial shear stress predicted
local plaque progression.
Provided evidence for differences in
endothelial shear stress as a driver
of local plaque progression.
Toutouzas et al. (52) Observational Measured carotid plaque
temperature in vivo using
microwave radiometry in 34
patients before endarterectomy
and controls, and compared with
ex vivo plaque histopathology.
Plaque temperature was higher in
cases versus controls, and higher
in plaques with thin ﬁbrous caps
and high expression of CD3, CD68,
and VEGF.
Identiﬁed plaque temperature, as
measured by microwave
radiometry, as a novel marker for
high-risk plaque.
3D ¼ 3-dimensional; AAD ¼ abdominal aortic diameter; ABI ¼ ankle brachial index; ACS ¼ acute coronary syndrome(s); CFR ¼ coronary ﬂow reserve; MACE ¼ major adverse cardiovascular event(s);
PET ¼ positron emission tomography; VEGF ¼ vascular endothelial growth factor; other abbreviations as in Table 1.
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1609(63). With respect to discrimination of high-risk plaque,
OCT permits evaluation of lipid content and macrophage
inﬁltration, and measurement of ﬁbrous cap thickness.
Limitations include inconsistent accuracy in discriminating
lipid plaque, similar optical properties between macrophage
accumulation and lipid plaque, artifacts, and lack of stan-
dardization of analysis of ﬁbrous cap thickness (64). Recent
publication of consensus standards for acquisition, mea-
surement, and reporting for OCT will facilitate its use for
both research and potential clinical applications (65).
Registries of patients undergoing 3-vessel OCT have
permitted observations about plaque composition in
different patient subsets. Key recent publications have
explored plaque morphology in the settings of diabetes and
ACS. In an analysis of 98 patients with 230 nonculprit
plaques, diabetes was associated with larger lipid volume
index and higher prevalence of calciﬁcation and thrombus,
with ﬁbrous cap thickness being inversely related toglycosylated hemoglobin (HbA1c) (66). TCFA and macro-
phage inﬁltration were most common in patients with
HbA1c 8%. In an analysis of 17 ACS patients with 45
nonculprit plaques, and 87 non-ACS patients with 203
nonculprit plaques, plaques in ACS patients were associated
with larger lipid volume index, thinner ﬁbrous cap (mean
70.2  20.2 mm vs. 103.3  46.8 mm, p < 0.001), and
greater frequency of TCFA (64.7% vs. 14.9%, p < 0.001),
macrophage inﬁltration (82.4% vs. 37.9%, p ¼ 0.001), and
thrombus (29.4% vs. 1.1%, p < 0.001) (67). OCT in
nonobstructive plaques has revealed imaging predictors of
plaque progression, including intimal laceration, micro-
channels, lipid pools, TCFA, macrophage content, and
intramural thrombi (68).
Perhaps most remarkably, OCT that is performed pre-
intervention in the setting of ACS has permitted in vivo
characterization of the mechanisms of plaque disruption.
Jia et al. (69), evaluating pre-intervention OCT ﬁndings of
Tomey et al. JACC Vol. 63, No. 16, 2014
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OCT evidence of plaque rupture in 43.7%, plaque erosion in
31.0%, and calciﬁed nodules in 7.9%. Compared with pla-
que rupture, plaque erosion was associated with younger age,
lower frequency of lipid plaque, and thicker ﬁbrous cap,
whereas calciﬁed nodules, as observed with IVUS, were
associated with older age.
In summary, although OCT still lacks a clinical indication
for use (and therefore reimbursement), this burgeoning body
of published data attests to the power of OCT as an imaging
tool. Our understanding of plaque biology has grown
through these OCT-based studies, and it will be interesting
to see whether OCT can challenge IVUS as a clinically
indicated imaging tool and as the preferred imaging mo-
dality for clinical studies using lesion- and vessel-based
endpoints.
Computed tomography. Several publications over the past
year have evaluated the utility of cardiac computed tomogra-
phy (CT) to describe high-risk plaque features and delineate
individual plaque components. Although CT identiﬁes pla-
que components with similar accuracy to RF-IVUS (70), an
important limitation of CT is that its spatial resolution does
not permit measurement of ﬁbrous cap thickness, preventing
its use for the identiﬁcation of TCFA.
A notable advance has been the identiﬁcation of the
napkin-ring sign, deﬁned as a ring-like attenuation pattern
of coronary atherosclerotic plaques on CT. Validated against
histological sections in an investigation of 21 coronary
arteries in 7 donor hearts, the napkin-ring sign identiﬁed
advanced atherosclerotic lesions with high speciﬁcity and
positive predictive value (71). In a subsequent prospective
study of 12,727 analyzed coronary segments and 1,174
plaques in 895 patients with more than 1-year follow-up
(mean 2.3  0.8 years), low-attenuation plaque, positive
arterial remodeling, and the napkin-ring sign emerged as
signiﬁcant, independent predictors of ACS (72).
CMR and molecular imaging. Previously used extensively
in the evaluation of carotid plaque, recent studies have moved
to describing the utility of CMR in characterizing coronary
plaque. In a study ofT1, T2, and ultrashort echo timeCMR in
28 plaques from ﬁxed post-mortem human coronary arteries,
CMR demonstrated high speciﬁcity and sensitivity for
detection of calciﬁcation (100% and 90%, respectively) and
lipid-rich necrotic core (90% and 75%, respectively), with
complete agreement in plaque histological classiﬁcation in 22
of 28 cases (weightedK¼ 0.6945, p< 0.0001) (73). Although
still experimental, these data are tantalizing and hopefully are a
glimpse of what the future may hold in terms of CMR and
in vivo coronary plaque imaging.
Imaging of molecular markers associated with plaque pro-
gression is among the most exciting emerging developments
in identiﬁcation of high-risk plaque (74,75). In general, these
approaches pair a probe designed to target cells or molecules
implicated in plaque progression with an imaging modality.
There are numerous pathways of interest that may be targeted
by molecular imaging such as cellular activation, phagocytosis,lipoproteins, metabolic activity, cell death, oxidative stress,
neovascularization, matrix metalloproteinase activity, intra-
plaque hemorrhage and thrombosis, and microcalciﬁcation
(76). The growing list of targets for molecular imaging now
includes macrophages, matrix metalloproteinases, cysteine
proteases, avb3 integrins, glucose transporter 1, and HDL
nanoparticles.
There are several imaging possibilities under investigation
for the detection of molecular markers, the most promising
currently being positron emission tomography (PET),
CMR, single-photon emission CT, spectral CT, and near-
infrared ﬂuorescence, each with relative advantages and
disadvantages, as reviewed previously (77). Of these,
18F-ﬂuorodeoxyglucose (FDG) PET has high sensitivity,
high availability, and perhaps the greatest promise in the
near term (78), but suffers from limited spatial resolution
and the need for radioactive isotopes. Use of 18F-FDG for
the purpose of coronary plaque–speciﬁc imaging is further
limited by uptake by neighboring cells, including car-
diomyocytes and smooth muscle cells, motivating the search
for more speciﬁc probes (79). 18F-sodium ﬂuoride may be
useful for this purpose. In a study of 37 patients with acute
myocardial infarction, Joshi et al. (80) demonstrated differ-
ential uptake of 18F-sodium ﬂuoride, but not 18F-FDG, in
ruptured (culprit) plaques compared with nonculprit plaques
(Fig. 3). Furthermore, in patients with stable angina, plaques
with high 18F-sodium ﬂuoride uptake were associated with a
higher likelihood of high-risk features on RF-IVUS than
were plaques without 18F-sodium ﬂuoride uptake. CMR
provides high spatial resolution without radiation exposure
to the patient, but has lower sensitivity and longer imaging
times (77); and recent questions have also been raised con-
cerning effects on lymphocyte DNA integrity (81).
Hybrid approaches incorporating both PET and CMR
are increasingly being used. This was nicely demonstrated
this year by Majmudar et al. (79) using zirconium-89–radi-
olabeled dextran nanoparticles for the purpose of macrophage
imaging. Using a mouse model, the investigators demon-
strated speciﬁc uptake of probe by macrophages rather than
other leukocytes, and increased uptake of probe in the aortic
roots of atherogenic mice compared with controls. Anti-
inﬂammatory therapy with a short interfering RNA–based
silencer of the monocyte-recruiting receptor CCR2 yielded a
decrease in probe signal. These ﬁndings provide an excellent
example of the promise of molecular imaging to ultimately
identify high-risk plaque and measure its response to therapy,
while at the same time highlighting the nascent state of play
in this area, which has yet to be validated in the clinic.
Certainly, it would seem fair to state that several more years
will be required before these modalities become available for
widespread clinical use.Measuring Plaque Response to Systemic Therapy
Statins and lipid plaque. HMG-CoA reductase inhibitors
(statins) alter the natural history of CAD, as evident in their
Figure 3 Focal 18F-Sodium Fluoride Uptake in Patients With Acute MI
Patient with acute ST-segment elevation myocardial infarction (MI) with (A) proximal occlusion (red arrow) of the left anterior descending artery on invasive coronary angiography
and (B) intense focal 18F-sodium ﬂuoride (tissue-to-background ratios, culprit 2.27 vs. reference segment 1.09 [108% increase]) uptake (yellow to red) at the site of the culprit
plaque (red arrow) on the combined positron emission and computed tomogram (PET-CT). Patient with anterior non–ST-segment elevation MI with (C) culprit (red arrow; left
anterior descending artery) and bystander nonculprit (white arrow; circumﬂex artery) lesions on invasive coronary angiography that were both stented during the index
admission. (D) After percutaneous coronary intervention, only the culprit lesion had increased 18F-sodium ﬂuoride uptake on PET-CT (tissue-to-background ratios, culprit 2.03 vs.
reference segment 1.08 [88% increase]). The ﬁgure was generated using Servier medical art (Servier, Suresnes, France). Adapted with permission from Joshi et al. (80).
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vention cohorts (82,83). Helping elucidate the mechanism
of beneﬁt, key imaging studies over the past year have
illustrated changes in plaque composition with statin
therapy.
In a prospective observational study of serial OCT,
grayscale IVUS, and integrated backscatter IVUS for
nontarget lesions in 42 patients undergoing percutaneous
coronary intervention (PCI) for stable CAD, Hattori et al.
(84) demonstrated signiﬁcant reductions in plaque volume
index (IVUS) and lipid volume index (OCT), and increase
in ﬁbrous cap thickness at a mean follow-up of 9 months in
patients treated with pitavastatin 4 mg compared with
control patients who refused statin therapy.
The YELLOW (Reduction in Yellow Plaque by Aggres-
sive Lipid Lowering Therapy) trial compared IVUS and
near-infrared spectroscopy ﬁndings in 87 patients undergoing
PCI for multivessel CAD with at least 1 obstructive non-
target lesion randomized to rosuvastatin 40 mg daily or
standard-of-care in 87 patients (85). Following 7 weeks ofdrug therapy, intensive statin therapy was associated with a
signiﬁcantly greater median reduction in maximal lipid core
burden index in 4 mm that remained signiﬁcant after
adjustment for baseline differences. Gross changes in plaque
morphology were not evident on IVUS, as has been re-
ported previously with intensive statin therapy after longer
follow-up (86). Nonetheless, the ﬁndings of the YELLOW
trial were notable in showing that even at this early time point,
changes consistent with plaque regression were evident
(Fig. 4). The ongoing YELLOW II trial seeks to identify
molecular mechanisms of these early plaque changes,
including the contribution of HDL functionality.
In an important IVUS subanalysis of SATURN (Study
of Coronary Atheroma by Intravascular Ultrasound: Effect
of Rosuvastatin vs. Atorvastatin), Puri et al. (87). examined
the effect of baseline atheroma volume on clinical outcomes
after 2 years of high-intensity statin therapy in 1,039 pa-
tients. Three provocative ﬁndings emerged. First, low-
density lipoprotein cholesterol (LDL-C) levels were similar
between patients with a higher versus a lower baseline
Figure 4 Plaque Lipid Core Burden Before and After Intensive Statin Therapy
Panels illustrate ﬁndings on coronary angiography, intravascular ultrasound (IVUS), and near-infrared spectroscopy for an atherosclerotic plaque in the mid left anterior
descending artery before (A) and 7 weeks after (B) initiation of intensive statin therapy. Images demonstrate reduction in total lipid core burden index (LCBI) and maximal LCBI
in a given 4 mm segment with no signiﬁcant change in angiographic diameter stenosis or plaque area as measured by IVUS. Reprinted with permission from Kini et al. (85).
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Second, despite achieving LDL-C levels <70 mg/dl with
high-intensity statin therapy, baseline coronary atheroma
volume remained strongly predictive of subsequent MACE,
with increasing baseline atheroma volume being associated
with greater cumulative MACE. These associations
remained signiﬁcant despite adjustment for LDL-C levels.
Third, and despite their increased MACE, patients with a
higher baseline coronary atheroma volume experienced
greater plaque regression and lumen expansion with potent
statin therapy, compared with patients with lesser atheroma
volume at baseline. In summary, it would appear that LDL-C
can account only partially for plaque volume, and that
although statins induce plaque regression, they do not nullify
the baseline burden of atherosclerotic disease. This study
speaks to the need to continue to seek novel ways to reduce
atherosclerotic disease burden, because there remains an
unmet need for further plaque and risk reduction in those
with more advanced disease.
Therapies for vascular inﬂammation. Several recent
manuscripts have described application of noninvasive
imaging, and in particular 18F-FDG-PET/CT, to evaluateeffects of statins and other more novel therapies on vascular
inﬂammation in human subjects.
Tawakol et al. (88) randomized 67 adults with established
atherosclerosis, who were not yet on statin therapy, to
atorvastatin 80 mg or 10 mg daily and measured the target-
to-background ratio of 18F-FDG uptake in the ascending
thoracic aorta at baseline, 4 and 12 weeks. With intensive
therapy, there was signiﬁcant reduction in target-to-
background ratio as early as 4 weeks.
Vucic et al. (89) reported the effects of a novelLXRa agonist,
R211945, on 18F-FDG PET/CT and dynamic contrast-
enhanced CMR inﬂammation and neovascularization in rab-
bit atherosclerotic plaques. Rabbits treated with the LXRa
agonist exhibited decreased plaque mean and maximum stan-
dard uptake values on 18F-FDG-PET/CT over time, sug-
gesting regression of inﬂammation, whereas rabbits treated
with atorvastatin showed no change and control subjects
showed increased standard uptake values. The LXRa agonist
was also associated with a decrease in macrophage, apolipo-
protein B, and oxidized phospholipid immunoreactivity.
A second study evaluated losmapimod, an inhibitor of
p38 mitogen-associated kinase, which has been associated
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sclerosis (90). Elkhawad et al. (90) randomized 99 patients
on stable doses of statin therapy to losmapimod 7.5 mg once
or twice daily or placebo for 12 weeks, with serial imaging of
vascular inﬂammation by 18F-FDG-PET/CT. There was
no difference in the primary endpoint of change from
baseline in average tissue-to-background ratio across all
vessel segments; however, there was a signiﬁcant reduction
in tissue-to-background ratio in active segments.
As an aside, within the last year, an old anti-inﬂammatory
agent, colchicine, was shown to signiﬁcantly reduce ischemic
events in patients with stable CAD (91). It is striking to
compare the wealth of imaging data with statins and other
agents against the paucity of data with colchicine. We ﬂag
colchicine as “low-hanging fruit” for plaque imaging studies
in the hope of stimulating mechanistic research exploring
the beneﬁcial effects of this agent.
A new frontier: PCSK9 inhibition. Perhaps the most
exciting therapeutic advance over the past year has been with
the inhibitors of proprotein convertase subtilisin/kexin type 9
(PCSK9), reviewed recently in the Journal (92).
The primary expected mechanism of PCSK9 inhibition
for modulation of atherosclerotic plaque is a dramatic
reduction in LDL-C. Interest in PCSK9 developed from
observations of subjects with loss-of-function mutations in
PCSK9 and extremely low levels of LDL-C, without sig-
niﬁcant adverse effects. Subsequent work has elucidated the
mechanism of PCSK9’s role in lipoprotein homeostasis,
leading to the development of several candidate monoclonal
antibodies and other agents to inhibit PCSK9. In the past
year, 4 phase 2 studies of a PCSK9 inhibitor, in patients
with hyperlipidemia on or off lipid-lowering therapy
(93,94), familial hyperlipidemia (95), and statin intolerance
(96), demonstrated consistent, large, sustained reductions in
LDL-C. Phase 3 studies are now being conducted to eval-
uate the effect of PCSK9 inhibition on clinical outcomes.
Of interest, beyond LDL-C reduction, it is evident that
PCSK9 is expressed in atherosclerotic plaques (97), and path-
ways are being explored connecting PCSK9 to vascular
inﬂammation and apoptosis. As clinical investigations of
PCSK9 inhibitors proceed, itwill be valuable to assess the impact
of these agents on the composition and behavior of stable and
vulnerable plaque. Insights in this regard may come from the
GLAGOV (GLobal Assessment of Plaque reGression With a
PCSK9 antibOdy as Measured by intraVascular Ultrasound)
study, which is currently in active enrollment (NCT01813422).
Targeting Local Therapy to High-Risk Plaque?
With the recent publication of positive results of the
PRAMI (Randomized Trial of Preventive Angioplasty in
Myocardial Infarction) (98), the question has resurfaced: is
there a role for preventive PCI? In the PRAMI trial, which
randomized patients with ST-segment elevation MI to
culprit lesion PCI with or without additional revasculariza-
tion of all nonculprit stenosis associated with 50%reduction in luminal diameter, the strategy of preventive
PCI was associated with a signiﬁcant reduction in the
composite primary endpoint of cardiac death, nonfatal MI,
or refractory angina (hazard ratio: 0.35, 95% CI: 0.21 to
0.58, p < 0.001) as well as the individual endpoint of
nonfatal MI (hazard ratio: 0.32, 95% CI: 0.13 to 0.75).
The results of the PRAMI trial and its effect size have
engendered signiﬁcant debate. Important unanswered sci-
entiﬁc questions include what proportion of ischemic
endpoint events in the PRAMI control group were derived
from unrevascularized nonculprit plaques. Also, as lesions in
PRAMI were deﬁned angiographically, we do not know the
nature of their composition. Nevertheless, although PRAMI
is unlikely to unilaterally change clinical practice, it has
opened what seemed a closed door to reconsider the role of
local therapies in cardiovascular prevention.
As another novel interventional strategy, investigators
have also begun to consider whether a preventive approach
of performing selective PCI on plaques assessed by imaging
to be high risk would improve clinical outcomes. However, a
selective approach of only performing PCI on high-risk le-
sions may be more challenging than expected, because pla-
ques at high risk of rupture may also be more likely to cause
complications when treated in the catheterization laboratory.
For example, by CT, target lesion low-attenuation plaque,
positive remodeling, and spotty calciﬁcation predict post-
PCI troponin elevation (99), and low-attenuation plaque,
positive remodeling, and circumferential plaque calciﬁcation
predict intraprocedural slow-ﬂow (100). Invasive identiﬁca-
tion of necrotic core and TCFA, by RF-IVUS and OCT,
similarly predicts distal microembolization and slow-ﬂow
(101). These ﬁndings have motivated interest in potential
techniques to limit these complications of PCI, such as distal
protection devices and mesh-covered stents designed to trap
and exclude thrombus and friable atheromatous debris dis-
rupted during PCI, as has been studied in the context of
primary angioplasty for acute ST-segment elevationMI (102).
With respect to selective PCI of high-risk lesions, and
although yet to be explored for this indication, newer bio-
logically resorbable stents are an intuitively attractive platform
for potential preventive PCI of high-risk lesions. There is a
perception that these devices may permit the interventional
treatment of offending lesions with many of the upsides, but
fewer of the permanent downsides, of current metallic stents.
Although it remains to be seenwhether this will be efﬁcacious,
we suspect that the ﬁeld is poised to embark on an era of
intense investigation of targeted local therapies for athero-
sclerosis founded upon sensitive and speciﬁc imaging mo-
dalities to detect vulnerable and high-risk lesions, combined
with “biologically friendly” resorbable stents that may be
loaded with targeted biological agents to prevent restenosis.
Conclusions
Although it will only become clear with the passage of
time, we believe 2012 to 2013 may prove to be a pivotal
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1614period in the ﬁeld of atherosclerosis. To the extent that the
past year saw a shift in interest back toward the high-risk
plaque (Fig. 1), this reﬂects the culmination of many years
of translational research and growing synergy between ad-
vances in molecular and cellular biology and plaque imaging.
It is critical to recognize that plaque composition imaging
remains in its infancy, still requiring much validation,
technological reﬁnement, and standardization of analysis. As
tools for discrimination of high-risk plaque gradually
improve, the central question will become: to what end? We
foresee utility for these technologies in investigating the
biology of plaque progression and regression in vivo that we
expect will eclipse simple imaging of plaque burden via CT
(103,104) or IVUS (87,105). Large, well-designed pro-
spective human trials powered to measure clinical outcomes
are now required to deﬁne the precise role of these advanced
imaging modalities in predicting risk, measuring response to
systemic therapy, and targeting local intervention. With this
excitement, it will be important in the coming years to
periodically check the momentum of the pendulum, main-
taining a balance between management of atherosclerosis as
a systemic disease and, where appropriate, understanding
and treating individually concerning lesions.
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